Iran’s Foreign Ministry said Wednesday that overnight American strikes on military targets near Bandar Abbas and the port city of Sirik had “effectively rendered the April 8 ceasefire meaningless,” a formal statement that the diplomatic framework agreed to after more than five weeks of fighting no longer applies. Explosions were reported at the Bandar Abbas airport and air base and at the Sirik naval base in the early morning hours, ABC News reported. U.S. Central Command said its forces had conducted “additional self-defense strikes targeting Iranian military surveillance capabilities, communications systems, and air defense sites across Iran, involving US Marine Corps, Air Force, and Navy assets firing precision-guided munitions.” Iran answered with drone and missile attacks on American military installations in Bahrain and Kuwait. An 11-year-old girl in Bahrain sustained minor injuries from falling drone debris when air defenses intercepted incoming fire.
The April 8 ceasefire was never a treaty. It carried no verification mechanism and no enforcement structure. What it had was both governments publicly acknowledging it. Iran’s Foreign Ministry statement Wednesday isn’t a new violation of the framework, which both sides have violated repeatedly since April. It’s the formal withdrawal of that acknowledgment. Those are different things. A violation strains a structure. A declaration of meaninglessness removes it.
The Strait of Hormuz has produced direct U.S.-Iranian military exchanges before without becoming the all-out war either side says it doesn’t want. In 1987, U.S. forces began escorting Kuwaiti tankers flying American flags as Iranian attacks on Gulf shipping intensified. The following spring, on April 18, 1988, American naval forces sank or disabled four Iranian vessels and destroyed two oil platforms in a single day’s operations, the largest U.S. surface naval engagement since World War II. Iran accepted the UN ceasefire with Iraq three months later. Ayatollah Khomeini described the decision in a message to the Iranian people as “more deadly than taking poison.” He accepted it because the war had exhausted a country running on ideology and momentum and running out of both. The current conflict began on February 28. It has been running 103 days. Whether either side has reached a comparable exhaustion, and whether this week’s escalation is a step toward an agreement or away from one, is the question the next several weeks will answer, NPR reported.
The 2026 FIFA World Cup opened Wednesday at the Estadio Azteca in Mexico City, where Mexico played South Africa in the tournament’s first match of a 48-team competition running through July 19. The final is scheduled at MetLife Stadium in East Rutherford, New Jersey. Mexican authorities declared June 11 a public holiday in Mexico City. The opening ceremony featured performances by Maná, Shakira, Andrea Bocelli, and Burna Boy, among others, Al Jazeera reported.
The last time the World Cup was played on North American soil was 1994, when the United States hosted a 24-team tournament across nine venues. Brazil beat Italy 3-2 on penalty kicks in the final at the Rose Bowl in Pasadena on July 17 of that year. That summer reached audiences who hadn’t been following soccer, and its effect on the sport’s infrastructure was built into the hosting agreement from the start: Major League Soccer launched in 1996 as a direct condition of the U.S. bid. The Azteca has hosted two previous World Cup finals, in 1970 and 1986. No other stadium in the world has hosted one. The 2026 tournament doubles the previous field to 48 teams and spreads the competition across three countries. Whether a tournament that size can generate the concentrated national feeling that made 1994 memorable is a question the next six weeks will begin to answer.
The Senate voted 48 to 50 on June 8 to reject an amendment attaching the Safeguard American Voter Eligibility Act to an immigration funding package, the third time the chamber has blocked the legislation in this session. Four Republicans joined every Democrat in voting no: Susan Collins of Maine, Lisa Murkowski of Alaska, Mitch McConnell of Kentucky, and Thom Tillis of North Carolina. President Trump had described the bill as his congressional allies’ “top priority,” Democracy Docket reported.
The Safeguard American Voter Eligibility Act would require documentary proof of citizenship, such as a passport or birth certificate, when registering to vote, and photo identification at the polls. It would also restrict where registration is permitted, effectively ending voter registration drives. Supporters argue current systems don’t adequately verify that registrants are citizens. Opponents argue the documentation requirements would prevent legal citizens from voting if they don’t have the specified documents readily available. The legislative math hasn’t changed: the same four Republicans who voted against the bill previously have done so again, and the Democratic caucus is unanimous. The question of what identification should be required to vote in America has been contested in courts and legislatures since the Voting Rights Act passed in 1965. This version hasn’t cleared the Senate.
The monthly Challenger, Gray and Christmas report released this week counted 97,006 announced job cuts at U.S.-based employers in May, up 16 percent from April and the highest May total since 2020, when pandemic layoffs drove the figure to nearly 400,000. The technology sector led with 38,242 cuts in May alone. What the report found unusual was the stated reason: artificial intelligence was cited in 38,579 announced cuts, accounting for 40 percent of all May layoffs, the highest monthly total since the firm began tracking that category in 2023, Challenger, Gray and Christmas reported.
Companies have attributed job cuts to automation in various forms for decades. What’s new here is the explicitness of the self-reporting. Historically, companies describe workforce reductions in terms of restructuring, strategic realignment, or efficiency initiatives. The May report found employers naming AI directly at a rate that has no precedent in the available data. For the year through May, AI has been cited in 87,714 announced cuts, already exceeding the 54,836 attributed to that reason in all of 2025. Andy Challenger, the firm’s chief revenue officer, said “companies are restructuring aggressively as they reposition for an AI-driven economy.” Whether that repositioning is producing a net gain or loss in employment over the full cycle is a question the monthly report can’t answer. It measures announcements, not hires. The full picture will take longer to develop.
A study of 111,646 women presented at the American Society of Clinical Oncology Annual Meeting this week found that women with excess body weight taking GLP-1 receptor agonist medications were roughly 30 percent less likely to develop breast cancer than comparable women not taking the drugs. The research was led by Elizabeth McDonald, a professor of radiology at the University of Pennsylvania Perelman School of Medicine, who analyzed breast imaging records from January 2022 through June 2025, Penn Medicine reported. About 13.7 percent of the women in the study had documented GLP-1 prescriptions.
The study is observational. It shows a correlation but can’t establish that the drugs caused the difference in incidence. The researchers have called for a large prospective trial to test the relationship directly. The ASCO presentation adds scale: more than 111,000 women is a substantial population, and a 30 percent difference in incidence isn’t a small signal. GLP-1 drugs were developed for Type 2 diabetes and expanded to obesity treatment. Separate studies have associated them with reduced cardiovascular risk and with reduced incidence of several other cancers. Whether those effects share a biological mechanism, and whether that mechanism can eventually be studied and applied independently of the drugs’ weight-loss function, is a line of research now several years old that hasn’t reached its final answer.
Phyllis Goodwin’s “At Large” column in the Ideas section published its latest installment Wednesday. “The Update” opens before six in the morning, when Phyllis’s phone has updated itself overnight, moved the alarm clock to a screen she hasn’t located yet, and is asking her to agree to a revised privacy policy before she can make a call. The column follows what happens next: the coffee maker now has firmware it wants to discuss; the television requires fresh consent before resuming what she was watching Tuesday night; the settings have reorganized under headings that weren’t there Monday. Phyllis meets all of this with the precise, wary attention of someone who was keeping perfectly good records before anyone arrived to improve them. It’s a genuinely funny piece about a genuinely modern condition: technology designed around constant improvement, experienced by someone who didn’t request the change and didn’t have a vote. That gap doesn’t close. It generates new columns. At Large: The Update.
One more thing. The New England Journal of Medicine published clinical trial results Wednesday for zorevunersen, a drug designed to treat Dravet syndrome, a rare and severe form of childhood epilepsy caused by a mutation in the SCN1A gene. Dravet syndrome typically begins in the first year of life. The seizures don’t respond well to most standard medications. There’s no cure, and many children with the condition have multiple prolonged seizures a day.
In two Phase 1 and 2 trials conducted across 81 patients between the ages of two and eighteen, those who received the full therapeutic doses of zorevunersen had motor seizure reductions of nearly 85 percent at three months, according to the published results. Across the patient group, seizure frequency fell between 59 and 91 percent. Children in the trials also showed improvements in quality of life and cognitive functioning. A Phase 3 trial is enrolling approximately 150 patients in the United States, United Kingdom, and Japan, with results expected in 2027 to support an FDA application. The regulatory path is still ahead. But a treatment that reduces seizures by 59 to 91 percent in children who have spent their lives having them is worth knowing about today.
It is Wednesday, June 11. Iran’s Foreign Ministry declared the April 8 ceasefire “meaningless” after new American strikes near Bandar Abbas and Sirik and fresh Iranian retaliatory attacks on U.S. installations in the Gulf; the FIFA World Cup opened at the Estadio Azteca in Mexico City, the first North American tournament since 1994; the Senate blocked the Safeguard American Voter Eligibility Act 48 to 50 for the third time, with four Republicans again voting no; the Challenger, Gray and Christmas report found AI cited as the reason for 40 percent of May job cut announcements, the highest monthly total ever recorded for that category; a study of more than 111,000 women at the ASCO Annual Meeting found GLP-1 drug users were roughly 30 percent less likely to develop breast cancer; and clinical trial results published in the New England Journal of Medicine showed 59 to 91 percent fewer seizures in children with Dravet syndrome treated with zorevunersen. That’s the day.
